Track CareDx, Inc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CareDx, Inc CDNA · Stock Open CareDx, Inc in new tab

77.88 USD
P/E
32.86
EPS
2.37
P/B
8.74
ROE
33.04
Beta
2.49
Target Price
94.43 USD
CareDx, Inc logo

CareDx, Inc

🧾 Earnings Recap – Q1 2026

Shares of CareDx, Inc declined 4.8% post-earnings as investors reacted negatively to a more cautious outlook and slower momentum in key business drivers. Management's revised strategy update and portfolio shifts did not fully allay concerns about deceleration in core growth metrics.

  • The company announced the divestiture of its Lab Products business and an acquisition of Navaris, signaling a pivot in portfolio priorities.
  • Management emphasized ongoing pipeline progress, including the upcoming AlloSure liver program and the planned launch of HistoMap kidney, but specifics on adoption or revenue contribution were limited.
  • Workflow integration remains a focus, with a target of 50% of testing volume through Epic-integrated sites by year-end; progress was noted, but ultimate impact remains to be demonstrated.
  • Clinical adoption outside core kidney testing (notably HeartCare and lung indications) was discussed, but updates suggested incremental rather than breakout momentum.
  • The updated 2026 outlook was highlighted on the call, but the market's negative reaction suggests investors remain concerned about growth trajectory and the impact of strategic repositioning.
📅
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
P/E32.86
EPS2.37
Book Value8.91
Price to Book8.74
Debt/Equity6.20
% Insiders3.210%
Growth
Revenue Growth0.39%
Earnings Growth10.67%
Estimates
Forward P/E49.79
Forward EPS1.56
Target Mean Price94.43

DCF valuation

Model fair value for CareDx, Inc (CDNA)
Result
Sign in to run the valuation for CDNA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Buy · mean target 94.43 USD (low 90.00, high 100.00) · as of 15 Nov 2026
Low 90.00
Mean 94.43
High 100.00
Price 77.88
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

CareDx, Inc Logo CareDx, Inc Analysis (CDNA)

United States Health Care Official Website Stock

Is CareDx, Inc a good investment? CareDx, Inc (CDNA) is currently trading at 77.88 USD. Market analysts have a consensus price target of 94.43 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 32.86. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: CareDx, Inc is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is 1.56.

Investor FAQ

Does CareDx, Inc pay a dividend?

No, it does not currently pay a dividend.

What asset class is CareDx, Inc?

CareDx, Inc is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of 2.37.

Company Profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.

Exchange Ticker
NMS (United States) CDNA
FRA (Germany) 1K9.F
STU (Germany) 1K9.SG
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion